The promise of nanoneuromedicine

Nanomedicine

Volumn 9, Issue 2, 2014, Pages 171-176

  Gendelman, Howard E ^a   Mosley, R Lee ^a   Boska, Michael D ^b   McMillan, Joellyn ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Drug targeting; Hyperthermia; Magnetic nanoparticles; MRI; Nanotoxicity

Indexed keywords

MAGNETIC NANOPARTICLE; NANOSPHERE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN DEGENERATION; DRUG TARGETING; GENE TARGETING; HUMAN; MULTIPLE SCLEROSIS; NANOMEDICINE; NANONEUROMEDICINE; NANOTOXICOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE;

HUMANS; NANOTECHNOLOGY; NEUROLOGY; SOCIETIES, MEDICAL;

EID: 84896715274     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.17     Document Type: Review

References (42)

1. Kanwar JR, Sun X, Punj V et al. Nanoparticles in the treatment and diagnosis of neurological disorders: Untamed dragon with fire power to heal. Nanomedicine 8(4), 399-414 (2012).
2. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev. 64(7), 686-700 (2012).
3. Urakami T, Kawaguchi AT, Akai Set al. In vivo distribution of liposome-encapsulated hemoglobin determined by positron emission tomography. Artif. Organs 33(2), 164-168 (2009).
4. Marsh JN, Senpan A, Hug et al. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond.) 2(4), 533-543 (2007).
5. Shapiro EM , Skrtic S, Koretsky AP. Sizing it up: Cellular MRI using micron-sized iron oxide particles. Magn. Reson. Med. 53(2), 329-338 (2005).
6. Kanwar JR, Sriramoju B, Kanwar RK. Neurological di sorders and therapeutics targeted to surmount the blood-brain barrier. Int. J. Nanomedicine. 7, 3259-3278 (2012).
7. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: Effect of administration route and magnetic field topography. J. Control Release 155(3), 393-399 (2011).
8. Yang B, Cai H, Qin W et al. Bcl-2-functionalized ultra small superparamagnetic iron oxide nanoparticles coated with amphiphilic polymer enhance the labeling efficiency of islets for detection by magnetic resonance imaging. Int. J. Nanomedicine. 8, 3977-3990 (2013).
9. Nel A, Swindells S, Bronich T, Gendelman HE. Nanomedicine and the fight against HIV/AIDS. Nanomedicine 9(2), 1-14 (2014).
10. Manickam DS, Brynskikh AM, Kopanic JL et al. Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury. J. Control Release 162(3), 636-645 (2012).
11. Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin Drug Deliv. 8(4), 415-433 (2011).
12. Mayeux R. Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26, 81-104 (2003).
13. Watson D, Castano E, Kokjohn TA et al. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer?s disease. Neurol. Res. 27(8), 869-881 (2005).
14. Singh S, Singh M, Gambhir IS. Nanotechnology for Alzheimer?s disease detection. Dig. J. Nanomater. Bios. 3(2), 75-79 (2008).
15. ee JH, Kang DY, Kim SU, Yea CH, Oh BK, Choi JW. Electrical detection of beta-amyloid (1-40) using scanning tunneling microscopy. Ultramicroscopy 109(8), 923-928 (2009).
16. Vestergaard M, Kerman K, Kim DK, Ha MH, Tamiya E. Detection of Alzheimer?s tau protein using localised surface plasmon resonance-based immunochip. Talanta 74(4), 1038-1042 (2008).
17. Yang J, Wadghiri YZ, Hoang DM et al. Detection of amyloid plaques targeted by USPIO-Abeta1-42 in Alzheimer?s disease transgenic mice using magnetic resonance microimaging. Neuroimage 55(4), 1600-1609 (2011).
18. Feng L, Long HY, Liu RK et al. A quantum dot probe conjugated with abeta antibody for molecular imaging of Alzheimer?s disease in a mouse model. Cell. Mol. Neurobiol. 33(6), 759-765 (2013).
19. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I et al. Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J. Am. Chem. Soc. 130(46), 15437-15443 (2008).
20. Podolski IY, Podlubnaya ZA, Kosenko EA et al. Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. J. Nanosci. Nanotechnol. 7(4-5), 1479-1485 (2007).
21. Triulzi RC, Dai Q, Zou J et al. Photothermal ablation of amyloid aggregates by gold nanoparticles. Colloids Surf. B Biointerfaces 63(2), 200-208 (2008).
22. Wilson B, Samanta MK, Santhi K, Sampath Kumar KP, Ramasamy M, Suresh B. Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer?s disease. J. Neurosci. Methods 177(2), 427-433 (2009).
23. Dauer W, Przedborski S. Parkinson?s disease: Mechanisms and models. Neuron 39(6), 889-909 (2003).
24. An Y, Tang L, J iang X et al. A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of alpha-synuclein. Chemistry 16(48), 14439-14446 (2010).
25. Yu J, Lyubchenko YL. Early stages for Parkinson?s development: Alpha-synuclein misfolding and aggregation. J. Neuroimmune Pharmacol. 4(1), 10-16 (2009).
26. Baron R, Zayats M, Willner I. Dopamine-, l-DOPA-, adrenaline-, and noradrenaline-induced growth of Au nanoparticles: Assays for the detection of neurotransmitters and of tyrosinase activity. Anal Chem. 77(6), 1566-1571 (2005).
27. Santos SG, Santana JV, Maia FF Jr et al. Adsorption of ascorbic acid on the C60 fullerene. J. Phys. Chem. B 112(45), 14267-14272 (2008).
28. Klyachko NL, Haney MJ, Zhao Y et al. Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine (Lond.) doi:10.2217/nnm.13.115 (2013) (Epub ahead of print).
29. Esposito E, Fantin M, Marti Met al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm. Res. 25(7), 1521-1530 (2008).
30. Trapani A, De Giglio E, Cafagna D et al. Characterization and evaluation of chitos an nanoparticles for dopamine brain delivery. Int. J. Pharm. 419(1-2), 296-307 (2011).
31. Huang R, Ke W, Liu Y et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J. Neurol. Sci. 290(1-2), 123-130 (2010).
32. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional protein delivery into neurons using polymeric nanop articles. J. Biol. Chem. 284(11), 6972-6981 (2009).
33. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet 369(9578), 2031-2041 (2007).
34. Hong S, Choi I, Lee S, Yang YI, Kang T, Yi J. Sensitive and colorimetric detection of the structural evolution of superoxide dismutase with gold nanoparticles. Anal Chem. 81(4), 1378-1382 (2009).
35. Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl. Biochem. Biotechnol. 151(2-3), 565-577 (2008).
36. Ali SS, Hardt JI, Dugan LL. SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: A structure-activity study. Nanomedicine 4(4), 283-294 (2008).
37. Bondi ML, Craparo EF, Giammona G, Drago F. Brain-targeted solid lipid nanoparticles containing riluzole: Preparation, characterization and biodistribution. Nanomedicine (Lond.) 5(1), 25-32 (2010).
38. Machtoub L, Bataveljic D, Andjus PR. Molecular imaging of brain lipid environment of lymphocytes in amyotrophic lateral sclerosis using magnetic resonance imaging and SECARS microscopy. Physiol. Res. 60(Suppl. 1), S121-S127 (2011).
39. Korn T. Pathophysiology of multiple sclerosis. J. Neurol. 255(Suppl. 6), 2-6 (2008).
40. Van Kasteren SI, Campbell SJ, Serres S, Anthony DC, Sibson NR, Davis BG. Glyconanoparticles allow pre-symptomatic In vivo imaging of brain disease. Proc. Natl Acad. Sci. USA 106(1), 18-23 (2009).
41. McAteer MA, Sibson NR, Von Zur Muhlen C et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat. Med. 13(10), 1253-1258 (2007).
42. Bsso AS, Frenkel D, Quintana FJ et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest. 118(4), 1532-1543 (2008).